Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline Review, H2 2017’, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

The report reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) therapeutics and enlists all their major and minor projects

The report assesses Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Overview

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Companies Involved in Therapeutics Development

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drug Profiles

axitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BXQ-350 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitrosylcobalamin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab Drug Profile

R&D Progress

pexidartinib hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Bexion Pharmaceuticals LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Epizyme Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Merck & Co Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Novartis AG, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Open Therapeutics LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Pfizer Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Plexxikon Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline by Vyriad Inc, H2 2017

List of Figures

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports